Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon (Nasdaq: ANNX) announced inducement equity awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on January 9, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Summary
Annexon (Nasdaq: ANNX) announced inducement equity awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on January 9, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4). In aggregate the hires received options to purchase 155,000 shares of common stock. The options have a 10-year term, an exercise price of $6.16 per share (the closing price on January 15, 2026, the grant date), and vest over 4 years with 25% vesting at the first anniversary and the remainder vesting monthly thereafter, subject to continued service.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ANNX
On Jan 20, the first trading day after this news, ANNX closed 1.48% above the previous close.
Data tracked by StockTitan Argus for the Jan 20 session.
Key Figures
- Target population
- nearly 10 million people
- Neuroinflammatory diseases addressed by Annexon platform
- New employees
- 2 non-executive employees
- Recipients of inducement equity awards
- Option shares granted
- 155,000 shares
- Aggregate options to purchase Annexon common stock
- Exercise price
- $6.16 per share
- Closing price on January 15, 2026, used as grant exercise price
- Option term
- 10 years
- Duration of inducement stock options
- Vesting period
- 4 years
- Total vesting duration for options
- Initial vesting cliff
- 25%
- Portion vesting on first anniversary of grant date
- Ongoing vesting rate
- 1/48th monthly
- Monthly vesting of remaining option shares after year one
Historical Context
-
Outlined 2026 priorities and multiple registrational milestones with cash runway guidance.
-
Filed MAA with EMA for tanruprubart in GBS with supporting Phase 3 data.
-
Announced presentation slot at J.P. Morgan Healthcare Conference with webcast access.
-
Granted a 19,000‑share stock option inducement with standard four‑year vesting.
-
Closed underwritten public offering of shares and pre‑funded warrants for $86.25M.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the new non-executive employees received options to purchase 155,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.